Lu S, Wu L, Jian H, Chen Y, et al. Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double Lancet Oncol 2022 Jul 28. pii: S1470-2045(22)00382.
PMID: 35908558